Spruce Biosciences, Inc. (SPRBD)
OTCMKTS · Delayed Price · Currency is USD
9.99
-1.41 (-12.34%)
At close: Aug 8, 2025
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $2.91M in the twelve months ending March 31, 2025, down -71.27% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
2.91M
Revenue Growth
-71.27%
P/S Ratio
1.93
Revenue / Employee
145.45K
Employees
21
Market Cap
5.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
| Dec 31, 2023 | 10.09M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Federal National Mortgage Association | 28.89B |
| Federal Home Loan Mortgage | 22.97B |
| Thai Airways International Public Company | 5.55B |
| Alpine Auto Brokers | 129.78K |
| Central Bancompany | 851.25M |
| First National of Nebraska | 1.89B |
| Jingbo Technology | 2.29M |
| Mechanics Bank | 381.61M |
Spruce Biosciences News
- 15 days ago - Spruce Biosciences Announces Reverse Stock Split - Business Wire
- 18 days ago - HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - GlobeNewsWire
- 2 months ago - Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market - Business Wire
- 3 months ago - Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 4 months ago - Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript) - Seeking Alpha
- 4 months ago - Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 8 months ago - Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder - Benzinga
- 8 months ago - Spruce Biosciences to wind down investment for genetic disorder drug - Reuters